China Archives

News and Trends 20 Jul 2022

WuXi Biologics to build new center in Singapore as part of $1.4B investment

WuXi Biologics, a global contract research, development and manufacturing organization (CRDMO), has announced a 10-year $1.4 billion investment plan. The plan aims to expand the company’s research, development, and large-scale drug substance and drug product (DS/DP) manufacturing capacity and capabilities in Singapore. The company will build a new site that will add 120,000L biomanufacturing capacity […]

July 20, 2022 - 2 minutesmins - By Jim Cornall

biotech investment asia pacific june 2022

In Depth 19 Jul 2022

The biggest Asia-Pacific biotech investments in June 2022

The lab automation player MegaRobo stole the show in the Asia-Pacific region in June with a mega Series C round of $300 million. Oncology firms Doma Biopharmaceutical and Tessa Therapeutics also led the private biotech investment rankings. The Chinese lab automation developer MegaRobo was the decisive winner of June’s biotech investments in the Asia-Pacific region. […]

July 19, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 19 Jul 2022

SINOVAC starts influenza vaccine trial in Chile

Sinovac Biotech Ltd., a provider of biopharmaceutical products in China, has initiated a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine in Chile through a collaboration with the Pontificia Universidad Católica de Chile. SINOVAC said the results aim to provide scientific evidence to support its influenza vaccine immunogenicity and protection capacity. This clinical […]

July 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Jul 2022

Trial for drug targeting cancerous tumors begins in China

A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […]

July 18, 2022 - 3 minutesmins - By Liza Laws

News and Trends 15 Jul 2022

Triastek forms pact with Eli Lilly to 3D print tablets for oral drug delivery

A new research collaboration between Triastek, Inc. and Eli Lilly and Company will leverage 3D printing technology to achieve precise targeting and programmed drug release in the intestine. The China-based Triastek has developed proprietary 3D printing technology that provides solutions for drug development. According to the agreement, Triastek and Lilly will focus on improving the […]

July 15, 2022 - 3 minutesmins - By Omnia Ibrahim

News and Trends 5 Jul 2022

Brii Bio takes hepatitis B treatment option

Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in […]

July 5, 2022 - 3 minutesmins - By Jim Cornall

China biotech company healthcare private

Best in Biotech 30 Jun 2022

The top five private biotech companies in China

China has a thriving biotech venture capital scene, with firms bagging impressive cash in the last few years. Check out our pick of five private healthcare biotech companies that have raised major rounds in China. China’s biotech industry has undergone a momentous shift in recent decades, evolving from a generics-focused space to a thriving biotech […]

June 30, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 27 Jun 2022

Chinese biotech company gets go-ahead for mRNA COVID-19 omicron trial in the Philippines

Jiangsu Recbio Technology Co., Ltd. has received clinical trial approval for R520A, a mRNA COVID-19 vaccine, from the Food and Drug Administration of the Philippines. R520A is an mRNA COVID-19 vaccine specifically targeting the Omicron variant. It was developed by Wuhan Recogen Biotechnology Co., Ltd., a subsidiary of the company. R520A adopts a self-developed lyophilization […]

June 27, 2022 - 1 minutemin - By Jim Cornall

News and Trends 21 Jun 2022

Therorna funding to accelerate circRNA-based platform

Therorna Inc., a Chinese biotech company specializing in the development of circular RNA (circRNA) technology-based new vaccines and therapies, including for COVID-19, has completed a $42 million series A financing round. The funding was co-led by MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital. […]

June 21, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us